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Paroxysmal Nocturnal Hemoglobinuria
Introduction
Paroxysmal nocturnal hemoglobinuria (PNH) is a rare,
acquired disease characterized by chronic intravascular
hemolysis caused by uncontrolled complement activation.1
The cellular abnormality in this life-threatening disease origi-
nates from a mutation in the phosphatidylinositol glycan
class A (PIGA) gene, resulting in a deficiency of glycosylphos-
phatidyl-inositol (GPI)-anchored complement regulatory pro-
teins, including CD55 and CD59, on the surface of blood
cells.1 Patients with chronic hemolysis experience a marked
increased risk of thromboembolism (TE), which may ulti-
mately lead to target organ damage and death.2,3
Retrospective analyses have reported that, despite best sup-
portive care, the 10-year survival rate in patients with PNH
ranged from 50% for patients diagnosed between 1940 and
19703-5 to 75% in a more recent series.6 TE is the leading cause
of mortality in patients with PNH, accounting for between
40% and 67% of deaths with known causes.7 Patients with
PNH also experience symptoms including fatigue, abdominal
pain, headache, shortness of breath, dysphagia, and erectile
dysfunction.1 These symptoms can be debilitating and signif-
icantly reduce the quality of life (QoL) of patients with PNH.8
PNH may develop in the absence of another bone marrow
disorder (BMD), as a condition secondary to BMDs such as
aplastic anemia (AA) or myelodysplastic syndrome, or as sub-
clinical PNH.1
The only potentially curative therapy for PNH is allogeneic
bone marrow transplantation; however, this procedure is
associated with substantial morbidity and mortality9-11 and,
consequently, is not an appropriate therapeutic option for
most patients. Historically, management of PNH was limited
to the use of supportive measures such as blood transfusions
and anticoagulation therapy. However, it has been reported
that the risk of TE in patients with PNH remains high even in
patients who have no clinical evidence of TE or are receiving
prophylactic anticoagulation,7,12 which is itself associated
with an increased risk of bleeding complications.13 In one
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Paroxysmal nocturnal hemoglobinuria is a rare, acquired disease associated with hemolytic anemia, bone marrow
failure, thrombosis, and, frequently, poor quality of life. The International PNH Registry is a worldwide, observa-
tional, non-interventional study collecting safety, effectiveness, and quality-of-life data from patients with a con-
firmed paroxysmal nocturnal hemoglobinuria diagnosis or detectable paroxysmal nocturnal hemoglobinuria clone,
irrespective of treatment. In addition to evaluating the long-term safety and effectiveness of eculizumab in a global
population, the registry aims to improve diagnosis, optimize patient management and outcomes, and enhance the
understanding of the natural history of paroxysmal nocturnal hemoglobinuria. Here we report the characteristics
of the first 1610 patients enrolled. Median disease duration was 4.6 years. Median granulocyte paroxysmal noc-
turnal hemoglobinuria clone size was 68.1% (range 0.01-100%). Overall, 16% of patients had a history of throm-
botic events and 14% a history of impaired renal function. Therapies included anticoagulation (31%), immuno-
suppression (19%), and eculizumab (25%). Frequently reported symptoms included fatigue (80%), dyspnea
(64%), hemoglobinuria (62%), abdominal pain (44%), and chest pain (33%). Patients suffered from poor quality
of life; 23% of patients had been hospitalized due to paroxysmal nocturnal hemoglobinuria-related complications
and 17% stated that paroxysmal nocturnal hemoglobinuria was the reason they were not working or were work-
ing less. This international registry will provide an ongoing, valuable resource to further the clinical understanding
of paroxysmal nocturnal hemoglobinuria. (Clinicaltrials.gov identifier:01374360) 
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ABSTRACT
study, spontaneous, long-term remission was observed in
approximately 15% of patients.4
In 2007, eculizumab (Soliris®, Alexion Pharmaceuticals,
Inc., Cheshire, CT, USA), a humanized monoclonal anti-
body that inhibits terminal complement activation, was
approved for the treatment of patients with PNH. A phase
II study (PILOT)14 and two phase III studies (TRIUMPH
and SHEPHERD)15,16 demonstrated that eculizumab was
well tolerated and provided a rapid, sustained, and clini-
cally meaningful reduction in hemolysis, fatigue, and
transfusion requirements, along with improved QoL.
Other studies have shown that eculizumab therapy in
patients with PNH is also associated with improvements
in pulmonary hypertension and renal function.2,17
Subsequent studies have demonstrated that eculizumab is
associated with a 92% reduction in the risk of TE
(P<0.001)7 and with a highly significant improvement in
patient survival to a level comparable to that of age-
matched healthy controls.3
The natural history of PNH is highly variable and has
previously been investigated by retrospective analyses
involving relatively small patient populations.4,6,18,19 The
burden of disease from the patient’s perspective has not
been previously documented. The International PNH
Registry was implemented to evaluate the safety and
effectiveness of eculizumab, to gather comprehensive data
on the natural history of PNH and the management of
patients with PNH, and to evaluate the clinical symptoms
and outcomes of the disease in order to better understand
its progression and variability on a global scale. The long-
term aim of the registry is to improve diagnosis and ther-
apeutic strategies, optimize patient management and out-
comes, enhance knowledge of pregnancy and related
issues, and better understand the natural history of the dis-
ease.
In this first publication of data from the International
PNH Registry, we report on the cross-sectional analysis of
demographic and clinical characteristics of patients
enrolled through June 30, 2012, and describe disease-asso-
ciated morbidities commonly experienced in patients with
PNH. In addition, we also report initial findings from a
subset of patients who had completed base-line study
questionnaires relating to impacts of the disease on vari-
ous measures, including QoL, symptomatology, and
employment status.
Methods
Patient population
The International PNH Registry is a prospective, non-interven-
tional, observational study. It collects information from patients
monitored in current medical practice irrespective of past, present,
or future treatment. The registry was approved by the institutional
review boards (or equivalent) of participating centers and all
patients provided written informed consent prior to inclusion. The
registry is sponsored by Alexion Pharmaceuticals, Inc., and is over-
seen by an independent executive committee of international PNH
experts.
Patients of any age with a clinical diagnosis of PNH (by any
applicable diagnostic method) and/or detectable PNH clone of
0.01% or over were eligible for inclusion in the registry. A PNH
clone was defined as a population of granulocytes and/or erythro-
cytes deficient in GPI.
Data collection
Data captured in the registry include patients’ demographics,
medical and treatment history, comorbid conditions, PNH clone
size, disease characteristics and outcomes, symptoms, PNH-spe-
cific treatments, PNH-related events, morbidity (including myelo-
proliferative disease, other malignancies, and infections), mortali-
ty, pregnancy (maternal and fetal outcomes), patient QoL, and
health resource utilization. Clinical data captured include lactate
dehydrogenase (LDH) levels, hemoglobin levels, transfusion
requirements, thrombotic events (identified using major adverse
vascular event categories), physician-reported renal dysfunction,
and other laboratory data. Specific information collected for
eculizumab-treated patients includes dosage and dose adjust-
ments, meningococcal vaccination status, infusion reactions, rea-
sons for treatment discontinuation, and outcomes associated with
discontinuation.
Patient medical information and study questionnaire data are
collected at study enrollment and every six months thereafter.
The patients’ questionnaires are collected at study enrollment
and during routine office visits close to the 6-month follow-up
time window and include QoL data based on the validated
Functional Assessment of Chronic Illness Therapy (FACIT)-
Fatigue20 and European Organisation for Research and
Treatment of Cancer Quality of Life Questionnaire version 3.0
(EORTC QLQ-C30)21 instruments, common PNH symptoms,
use of health care resources including hospitalizations, work sta-
tus and time lost from work due to PNH, and treatment satisfac-
tion.
Statistical analysis
Continuous variables were described using standard summary
statistics; categorical variables were described using frequencies
and percentages. Group differences were determined using analy-
sis of variance or the Student’s t-test for continuous variables and
χ2 tests for categorical variables. Non-parametric Wilcoxon and
Kruskal-Wallis tests were used for laboratory results (e.g. granulo-
cyte clone size and LDH) with non-normal distributions. P<0.05
was considered statistically significant..
Patient-reported symptoms, history of TE, and transfusion
requirements were stratified by PNH clone size at enrollment
(<10%, 10-49%, and ≥50%), diagnosis (current or prior) of AA or
other BMD, and LDH level (<1.5 or ≥1.5 x upper limit of normal
(ULN), the higher levels having been shown to be associated with
significantly increased risks of TE and mortality22,23). Clone size
categories were used for analyses, as their bimodal distribution
limits their suitability for consideration as a continuous variable.
For the EORTC QoL and FACIT-Fatigue assessments, lower
scores indicate a poorer QoL and increased levels of fatigue.
Differences in average scores between groups of 5 points or
over24 or 3 points or over,25 respectively, are considered clinically
meaningful.
Results
Patients’ demographics and clinical characteristics
As of June 30, 2012, 1610 patients from 273 centers in 25
countries were enrolled in the International PNH Registry
(Online Supplementary Table S1). Overall, 92.5% of patients
were from Europe and North America and 87.5% of
patients were Caucasian. The remaining patients were
Asian/Pacific Islanders (5.0%), of African descent (3.5%),
Native/Aboriginal (0.2%), or of other/unknown ethnici-
ty/race (3.9%).
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Patients’ demographics and clinical characteristics of the
1610 enrolled patients are provided in Table 1. Median
patient age at enrollment was 42 years (range 3-99 years),
and 53.2% of patients were female. Median PNH duration
from disease start to enrollment was 4.6 years, with a min-
imum of less than 1 year and a maximum of 47 years.
Overall, 774 (48.1%) of the patients had been diagnosed
with one or more types of BMD, including AA or
hypoplastic anemia (n=701; 43.5%), myelodysplastic syn-
dromes (n=93; 5.8%), myelofibrosis (n=7; 0.4%), and/or
acute myeloid leukemia (n=6; 0.4%). In the 900 of 1610
patients who had not received eculizumab in the 12
months prior to enrollment and for whom LDH values
were available, the median LDH level at the time of enroll-
ment was approximately twice the ULN. A history of any
prior thrombotic event was reported in 250 patients
(15.5%), with the majority of these patients (169 of 250,
67.6%) having experienced just one event. A similar num-
ber of patients (n=223,13.9%) had a history of impaired
renal function. At enrollment, 31.1% of patients were
receiving anticoagulation therapy, 18.7% immunosup-
pressive therapy, and 8.3% pain medication; approximate-
ly 25% of the patients were being treated with eculizum-
ab (Table 1). At the time of analysis, completed base-line
patients’ questionnaires relating to symptoms of PNH,
QoL, and work were available for 856 of the 1610 (53%)
enrolled patients. 
Due to the observational nature of this study, the num-
ber of patients contributing data to each assessment was
not consistent. In addition, as eculizumab reduces hemol-
ysis and prevents release of LDH, patients who had
received eculizumab at any time in the 12 months prior to
enrollment were excluded from all data summaries
assessed by LDH levels. A graphical summary of the num-
ber of patients included in each assessment, along with the
criteria defining each subpopulation, is provided in Online
Supplementary Figure S1.
PNH clone size
The median granulocyte clone size at enrollment was
68.1% (Table 1), and the entire range of clone sizes was
represented, from 0.01% (the minimum inclusion criterion
for enrollment) through 100%. The median clone size was
significantly larger in patients without a history of BMD
than in patients who had at any point been diagnosed
with AA (83% vs. 35%; P<0.001 by Wilcoxon test). The
distribution of clone sizes varied with history of BMD:
clone sizes of 50% or over and less than 10% were report-
ed in, respectively, 34% and 40% of patients with a histo-
ry of AA compared with 76% and 8% of patients without
a diagnosis of BMD other than PNH.
In patients who had not received eculizumab in the 12
months prior to study enrollment, median LDH levels gen-
erally increased with PNH clone size category (P<0.001 by
Kruskal-Wallis test) and in patients with no history of
BMD other than PNH compared with those patients ever
diagnosed with AA (Figure 1A). There was also a signifi-
H. Schrezenmeier et al.
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Table 1. Patients’ demographics and clinical characteristics at enroll-
ment into the International PNH Registry.
Parameter                                                                          Patients
                                                                                         (n=1610)
Age, years, median (range)                                                           42 (3-99)
Females, n (%)                                                                               857 (53.2)
Age at disease start, years, median (range)                             32 (3-87)
Disease duration, years, median (range)                               4.6 (<1-47)
Lactate dehydrogenase, ×ULN,                                            1.96 (0.65, 10.32)
median (5th, 95th percentile)a                                                                 
Hematologic parameters, median (5th, 95thpercentile)
Hemoglobin, g/L (n=1425)                                                        106 (70, 145)
Platelets, ×109/L (n=1430)                                                        131 (19, 271)
Absolute neutrophils, ×109/L (n=1275)                                1.7 (0.00, 5.10)
Absolute reticulocytes, ×109/L (n=971)                                 113 (27, 400)
Reticulocytes, % (n=1024)                                                      3.6 (0.82, 13.06)
Granulocyte clone size, %,                                                     68.1 (0.36, 99.30)
median (5th, 95th percentile)
<10%, n (%)                                                                                     280 (17.4)
10-49%, n (%)                                                                                  247 (15.3)
≥50%, n (%)                                                                                     832 (51.7)
Unknown, n (%)                                                                              251 (15.6)
History of thrombotic events, n (%)b                                         250 (15.5)
1                                                                                                          169 (10.5)
2                                                                                                            45 (2.8)
3                                                                                                            19 (1.2)
4+                                                                                                         10 (0.6)
Unknown                                                                                              7 (0.4)
Time (years) since most recent thrombotic event,             3.8 (<1-45)
median (range)                                                                                        
History of impaired renal function, n (%)b                               223 (13.9)
Anticoagulation therapy, n (%)b,c                                                 501 (31.1)
Immunosuppressive therapy, n (%)b,c                                        301 (18.7)
Pain medication, n (%)b,c                                                                133 (8.3)
Eculizumab, n (%)c,d                                                                       411 (25.5)
aIncludes only patients who had not received eculizumab in the year prior to enrollment
and who had LDH value available (n=900). bData not available for 60 patients (3.7%).
cAny use in the 12 months prior to enrollment. dAn additional 80 patients (5.0%) were
reported as having received treatment with eculizumab, though the dates of administra-
tion were unknown. PNH: paroxysmal nocturnal hemoglobinuria; ULN: upper limit of
normal; BMD: bone marrow disorder; AA: aplastic anemia.
Table 2. Treatment receiveda prior to enrollment into the International
PNH Registry by history of AA.
Treatment                        Number (%) of patients
                                                                     Ever                  With no
                                                                diagnosed               history
                                                                   with AA                of BMD
                                                                  (n=701)               (n=776)
Anticoagulation therapyb                                 147 (21.0)                326 (42.0)
Immunosuppressive therapyb,c                       270 (38.5)                  22 (2.8) 
Eculizumab therapyb                                        131 (18.7)                262 (33.8)
Red blood cell transfusiond                           262 (37.4)                266 (34.3)
Immunosuppressive therapyc plus:
Anticoagulation                                                   35 (5.0)                     6 (0.8)
Eculizumab                                                          37 (5.3)                     8 (1.0)
Red blood cells                                                 123 (17.6)                  13 (1.7)
Anticoagulation plus:
Eculizumab                                                          53 (7.6)                  108 (13.9)
Red blood cells                                                   63 (9.0)                  124 (16.0)
Eculizumab plus red blood cells                    60 (8.6)                   84 (10.8)
Bold values indicate statistically significant difference between groups (P<0.001) calcu-
lated from χ2 test for categorical variables and Student’s t-test for continuous variables.
aPatients may have received more than 1 type of treatment. bIn prior 12
months.cImmunosuppressive therapy includes cyclosporine and/or anti-thymocyte glob-
ulin. dIn prior 6 months. PNH: paroxysmal nocturnal hemoglobinuria; AA: aplastic ane-
mia; BMD: bone marrow disorder.
cant increase in the percentage of patients with LDH levels
≥1.5 x ULN as PNH clone size increased, going from 8%
of patients with a clone size less than 10% to 55% of
patients with a clone size of 10-49% and 83% of patients
with a clone size 50% or over (Figure 1B).
In patients who had not received eculizumab in the 12
months prior to enrollment, there was a positive correla-
tion between history of thrombosis and clone size at
enrollment: 5.3% of patients with clone size less than
10% had a history of thrombosis and 7.7% of patients
with clone size 10-49% had such a history, whereas
15.4% of patients with clone size 50% or over had such a
history (P<0.001). In addition, a larger percentage of
patients with LDH ≥1.5 x ULN at enrollment, compared
with LDH <1.5 x ULN at enrollment reported a history of
thrombosis (15.6% vs. 8.4%; P<0.001) (Figure 2A).
Concomitant therapies
The number of patients receiving anticoagulation thera-
py or immunosuppressive therapy in the 12 months prior
to enrollment and the number of patients receiving red
blood cell transfusions in the six months prior to enroll-
ment are shown in Table 2. Compared with patients with
no history of BMD, patients who had at some point been
diagnosed with AA were less likely to have received treat-
ment with anticoagulants (21.0% vs. 42.0%; P<0.001) or
with eculizumab (18.7% vs. 33.8%; P<0.001), but they
were more likely to have received immunosuppressive
therapies such as cyclosporine and/or anti-thymocyte
globulin (38.5% vs. 2.8%; P<0.001). There was no signifi-
cant difference between these patient groups in the per-
centage who had received red blood cell transfusions in
the six months before study enrollment (P=0.21), though
patients who had at some point been diagnosed with AA
received a significantly greater mean number of units of
packed red blood cells during this time frame compared
with patients with no history of BMD (9.0 vs. 6.8;
P=0.001).
Paroxysmal Nocturnal Hemoglobinuria Registry
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Figure 1. LDH concentration. (A) Median LDH concentration at enroll-
ment by PNH clone size and diagnosis. (B) Percentage of patients
with LDH <1.5×ULN or ≥1.5×ULN by PNH clone size. Only includes
patients who had not received eculizumab in the 12 months prior to
study enrollment.
Figure 2. Thrombosis and red blood cell transfusion history. (A)
Percentage of patients with a history of thrombosis by PNH clone size
and LDH level at enrollment. (B) Percentage of patients receiving red
blood cell transfusion in the year prior to enrollment by PNH clone
size and diagnosis. Only includes patients who had not received
eculizumab in the 12 months prior to study enrollment.
Table 3. Anticoagulant use (within 12 months prior to enrollment) by
selected characteristics.
                                                                      N. (%)                     P
                                                                  of patients                   
History of thrombotic events                                                                      
No (n=1300)                                                         318 (24.5)                   <0.01
Yes (n=250)                                                          176 (70.4)                        
Granulocyte clone sizea                                                                                 
<10% (n=280)                                                        26 (9.3)                     <0.01
10%-49% (n=247)                                                 42 (17.0)                         
≥50% (n=832)                                                      359 (43.1)                        
Lactate dehydrogenasea,b                                                                              
<1.5×ULN (n=384)                                              70 (18.2)                    <0.01
≥1.5×ULN (n=516)                                             201 (39.0)                        
aRecorded at time of enrollment. bExcludes patients who received eculizumab in the year
prior to enrollment. 
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Compared with patients with no history of BMD, a sig-
nificantly greater percentage of patients who had at some
point been diagnosed with AA had received treatment
with immunosuppressive therapies plus anticoagulants,
eculizumab, or red blood cell transfusions (all P<0.001)
(Table 2). In contrast, significantly more patients with no
history of BMD had received treatment with anticoagula-
tion therapy plus eculizumab or red blood cell transfusions
(both P<0.001) (Table 2).
Patients were significantly more likely to have received
anticoagulation therapy in the 12 months prior to enroll-
ment if they had a history of thrombosis, a granulocyte
PNH clone size 50% or over, or an LDH level ≥1.5 x ULN
(Table 3). Figure 2B shows the percentage of patients who
received red blood cell transfusions by diagnosis and PNH
clone size. Patients who had at some point been diag-
nosed with AA were more likely to have received a blood
transfusion in the six months prior to enrollment. This dif-
ference reached statistical significance in patients with
clone sizes over 50% (P=0.02).
PNH symptoms
Of the 856 patients for whom self-reported symptom
data were available (i.e. patients with a base-line question-
naire), a total of 799 patients (93.3%) reported at least one
symptom associated with PNH. The percentage of
patients reporting common symptoms associated with
PNH in the past six months is shown in Online
Supplementary Figure S2. Commonly reported symptoms
included fatigue (80%), dyspnea (64%), headache (63%),
and hemoglobinuria (62%), and 38% of male patients had
experienced erectile dysfunction. Although fatigue was
the most frequently reported symptom, 91.4% of patients
(782 of 856) reported at least one symptom other than
fatigue, whereas only 2.0% of patients (17 of 856) report-
ed fatigue and no other symptoms.
Although each of the common PNH-related symptoms
were reported in all categories of clone size, patients with
clone sizes 50% or over reported significantly more hemo-
globinuria, dyspnea, abdominal pain, scleral icterus, erec-
tile dysfunction, and dysphagia (Figure 3A). There were
no significant differences in the prevalence of fatigue,
headache, dyspnea, or confusion between clone size cate-
gories. The most frequently reported symptom was
fatigue, reported in over 75% of patients in each clone size
category. However, 83.3% of patients with clone size less
than 10%, 89.3% with clone size 10-49%, and 93.3%
with clone size 50% or over reported at least one symp-
tom other than fatigue, whereas only 4.0%, 3.6%, and
0.8% of patients, respectively, reported fatigue and no
other symptoms. In patients who had not been treated
with eculizumab, the prevalence of dyspnea, hemoglobin-
uria, abdominal pain, scleral icterus, chest pain, and dys-
phagia was significantly greater in patients with LDH ≥1.5
x ULN at enrollment than in patients with lower LDH lev-
els (Figure 3B). There were no significant differences in the
prevalence of confusion, headache, fatigue, or erectile dys-
function between patients with LDH levels ≥1.5 x ULN
and those with LDH levels <1.5 x ULN. Overall, 95.9% of
patients with LDH ≥1.5 x ULN reported at least one symp-
tom other than fatigue, whereas only 0.6% of patients
with elevated LDH levels reported fatigue and no other
symptoms. Similarly, 88.7% of patients with LDH 
<1.5 x ULN had symptoms other than fatigue, while only
2.0% reported fatigue alone.
For the majority of the patient-reported PNH-related
H. Schrezenmeier et al.
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Figure 3. Patient-reported PNH symp-
toms. (A) Patient-reported symptoms by
PNH clone size. (B) Patient-reported
symptoms by LDH level. Only includes
patients who had not received eculizum-
ab in the 12 months prior to study
enrollment. *Statistically significant.
†Male patients only; n=62, 68, and 222.
‡Male patients only; n=82 and 134.
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symptoms, history of BMD was not associated with
prevalence of the symptom. However, hemoglobinuria,
scleral icterus, and dysphagia were significantly more
common in patients never diagnosed with BMD (all
P<0.001).
QoL, hospitalization, and employment
Patient-reported EORTC QLQ-C30 QoL and FACIT-
Fatigue assessments indicated that, compared with
patients without a history of thrombosis, patients with a
prior TE had significantly lower global health status/QoL
(P=0.01), physical functioning (P<0.01), and social func-
tioning (P=0.02) and significantly greater fatigue (P=0.04)
(Online Supplementary Figure S3).
Statistically significantly lower QoL scores for all
EORTC domains were reported by patients who had
reported a clinical symptom of abdominal pain, chest pain,
confusion, dysphagia, dyspnea, erectile dysfunction,
fatigue, headache, hemoglobinuria, or scleral icterus in the
six months prior to completing the baseline questionnaire
compared with patients who had not experienced the
symptom. All results were highly significant (P<0.0001)
with the exception of emotional functioning for patients
with erectile dysfunction (P=0.039), physical functioning
for patients with hemoglobinuria (P=0.003), and emotion-
al and cognitive functioning in patients with scleral icterus
(P=0.001 and P=0.007, respectively).
In the six months prior to completion of the base-line
questionnaire, 194 of 856 patients (22.7%) reported being
hospitalized due to their PNH. Patients were significantly
more likely to be hospitalized if they had a history of
thrombosis or had experienced self-reported PNH-related
symptoms of scleral icterus, chest pain, dysphagia,
abdominal pain, hemoglobinuria, dyspnea, or fatigue in
the past six months (all P<0.01) (Online Supplementary
Figure S4).
The impact of PNH on a patient’s employment was
assessed in patients aged 18-59 years. Eighty-eight of 506
patients (17.4%) reported PNH as the reason they were
either not working or working less (e.g. part time rather
than full time). Of the 312 full-time or part-time workers,
82 (26.3%) had missed work in the past six months for
reasons related to PNH.
Discussion
As of June 30, 2012, the International PNH Registry had
enrolled 1610 patients from 5 continents, with completed
patient questionnaires at enrollment available for 856
patients. Collection of outstanding data, as well as new
recruitment into the registry, is ongoing. The current
analysis evaluated the base-line characteristics of the
enrolled population and investigated the burden of disease
in terms of symptomatology and clinical outcomes. As the
questionnaires completed at enrollment are largely con-
cerned with the patients’ medical history, much of the
data are retrospective. However, these base-line data are
an important foundation for future analyses on prospec-
tively collected data.
Assessing data from an extensive population is impor-
tant, particularly for rare conditions, as the disease course
can vary significantly among patients; at enrollment our
population has an age range spanning almost 100 years, a
disease duration of less than one to 47 years, and granulo-
cyte PNH clone sizes ranging from less than 1% to 100%.
Given these variations, associations between patients’
characteristics and outcomes and determination of robust
therapeutic strategies can be achieved only via an interna-
tional registry.
The level of morbidity was high in our patient popula-
tion: at enrollment, 43.5% had a history of AA or
hypoplastic anemia, 15.5% had experienced at least one
TE, and 13.9% had a history of impaired renal function.
The majority of patients not treated with eculizumab had
LDH concentrations ≥1.5 x ULN, a level associated with
significantly increased risks of TE and mortality.22,23 Our
analyses suggested an association between PNH granulo-
cyte clone size and LDH levels; in patients with a clone
size less than 10%, median LDH levels were towards the
ULN, with only 8% of patients having LDH ≥1.5 x ULN,
whereas in patients with a clone size 50% or over, median
levels were to >4.0 x ULN and 62% of patients had LDH
≥1.5 x ULN. Elevated LDH levels were also associated
with higher prevalence of TE and symptoms such as
abdominal pain, chest pain, and hemoglobinuria, all signif-
icant risk factors for TE.23
It is perhaps not surprising that a significantly larger per-
centage of patients who at some point have been diag-
nosed with AA had received immunosuppressive therapy
but less often received anticoagulation compared with
patients with no history of BMD. This latter group of
patients was significantly more likely to have been treated
with eculizumab; however, the percentage of patients
requiring red blood cell transfusions appeared to be inde-
pendent of underlying BMD.
Not only is thrombosis, the leading cause of death in
PNH,7 associated with a significant risk for mortality, but
patients experiencing a TE are 5-fold more likely to expe-
rience subsequent thrombotic events.5,6,26 Our findings
demonstrate that PNH patients at all clone sizes may have
a history of thrombosis, and patients with larger clones
were more likely to have a history of thrombosis. These
analyses suggest that all patients with PNH are at risk for
thrombosis. This finding indicates that all patients should
be routinely monitored for signs and symptoms of TE,
including clinically evident hemolysis and abdominal pain.
Overall, 31.5% of patients with a PNH clone size  less
than 10% had required at least one red blood cell transfu-
sion in the year prior to enrollment. As the majority of
patients with this PNH clone size for whom LDH assess-
ments at enrollment were available did not show signs of
elevated hemolysis, the reason for transfusions is most
likely related to an underlying BMD. These and other con-
comitant conditions may also be the cause of some of the
symptoms classified as “PNH related”. It should be noted
that not all of the transfusion, symptom and other data
collected at enrollment may be directly related to hemoly-
sis due to PNH, though collection and analysis of all such
data are important in order to provide greater insight into
the course of the disease and help to identify patients at
risk of TE.
Our results showed that patients were significantly more
likely to have been prescribed anticoagulant therapy if they
had a history of TE, a larger granulocyte clone size, or ele-
vated LDH concentrations. It must be remembered that
these factors are not mutually exclusive but interrelated.
Common PNH-related symptoms were experienced by
over 93% of patients for whom data was available.
Although significantly more patients with a clone size
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50% or over experienced hemoglobinuria, abdominal
pain, scleral icterus, dysphagia, and erectile dysfunction, a
substantial number of patients with a clone size  less than
10% also experienced these symptoms, indicating that
clone size alone is not a good indicator of burden of dis-
ease. The percentage of patients reporting PNH-related
symptoms was greater in those with LDH levels 
≥1.5 x ULN, with, for example, abdominal pain, a symp-
tom associated with a 3.6-fold greater risk of thrombosis,27
being significantly more common in patients with elevat-
ed LDH levels. Overall, our results confirm that patients
with PNH and elevated LDH levels are at increased risk of
experiencing complications of PNH associated with
increased risk of TE, mortality, and poor QoL.
Reference values for FACIT-Fatigue28 give a mean fatigue
score of 43.6 in the general population and 40.0 in non-
anemic cancer patients. The lower scores of 35.9 and 33.4
in patients without and with a history of thrombosis,
respectively, indicate that PNH patients have a clinically
meaningful greater level of fatigue29 than either of these
other 2 populations. Similarly, the EORTC global health
QoL assessments indicated that patients with PNH had a
clinically meaningful worse QoL22 (with mean scores of
63.7 and 57.5 in patients without and with a history of
thrombosis, respectively) than the general population (ref-
erence score 71.230) and similar QoL scores to those seen
in cancer patients.28 These findings show that PNH has a
clinically meaningful impact on QoL in all patients, with
the occurrence of a thrombotic event having a significant-
ly greater impact on patient levels of fatigue and overall
QoL.
The EORTC scores also showed that global health sta-
tus in patients with PNH is most affected by fatigue, con-
fusion, and chest pain; these symptoms also significantly
impact physical, role, and emotional functioning.
Abdominal pain significantly affects global health status,
particularly in terms of role, emotional, and cognitive
functioning. This is not surprising given that abdominal
pain and chest pain have been associated with a greater
risk of thrombosis and mortality.27
PNH has wide-ranging effects on patients’ lives. The
symptoms associated with the disease have serious conse-
quences and are frequently devastating; one-quarter of
PNH patients in the registry had been hospitalized and
one-third had missed work due to PNH. Approximately
one in 7 patients were not working or worked less due to
PNH.
This large, global PNH registry of patients observed in
clinical practice will continue to prospectively evaluate
disease burden and the long-term natural history of PNH
and treatment outcomes. The breadth and diversity of the
registry provides an excellent basis for investigating
research questions that may not be answerable from a sin-
gle institution or country, and the registry has the addi-
tional advantages of collecting both clinical and patient-
reported data and collecting these data both at enrollment
and prospectively. The International PNH Registry will
provide a valuable ongoing resource to further the clinical
understanding of this rare, life-threatening disease.
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